Mangoceuticals (MGRX) Q1 2026 earnings summary

Executive summary

• Report covers the quarter ended March 31, 2026, for a telemedicine-focused men's wellness company offering compounded and FDA-approved products for ED, hair loss, hormone therapy, and weight management.

• Revenues declined year-over-year due to focus on website development and targeted product testing.

• The company continues to face recurring net losses and requires additional funding to sustain operations.

Financial highlights

• Revenue for Q1 2026 was $67,864, down from $109,306 in Q1 2025.

• Net loss for Q1 2026 was $3,403,141, an improvement from $4,839,489 in Q1 2025.

• Cash on hand at March 31, 2026, was $174,562, down from $1,486,338 at year-end 2025.

• Total assets were $14.4 million; total liabilities were $974,571; accumulated deficit reached $44.1 million.

• Stock-based compensation increased to $1,647,821 from $1,045,479 year-over-year.

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and support growth initiatives.

• Plans include expanding product offerings, enhancing technology, and pursuing strategic acquisitions, subject to available capital.

• The company is exploring strategic alternatives to maximize shareholder value, including mergers and acquisitions.